Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
From the blog
The ONCOS-102 Vaccine Was Just Given the Fast-Track Designation
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
Genetic Testing Could Help Reduce Mesothelioma Cases and Help the Survival of Those Suffering from the Disease
Researchers believe that early genetic testing for genetic mutations can help reduce the cases of mesothelioma and can help increase the survival of those suffering from the disease. Researchers found that new mutations in the BLM gene were making people more susceptible to developing mesothelioma after being exposed to asbestos.[…]
Nivolumab Can Help Increase the Survival in Mesothelioma Patients Whose Cancer Has Relapsed
A study in the United Kingdom involving 332 patients who cannot receive surgery (unresectable) found that patients whose mesothelioma has relapsed can be treated with nivolumab safely. Nivolumab is an immunotherapy drug known as Opdivo, which is popular for treating non-small cell lung cancer. Opdivo is promising because it is[…]
Gemcitabine Used as a Maintenance Therapy Could Help Mesothelioma Patients Live Longer
Using maintenance therapy with gemcitabine alongside chemotherapy can help increase survival in patients compared to patients just receiving palliative care. Gemcitabine is an antimetabolite, which prevents cancer cells from dividing into new cancer cells. Chemotherapy is usually the first line treatment for mesothelioma, and if patients are able to receive[…]
SMART Mesothelioma Procedure Could Extend the Lives of Certain Mesothelioma Patients
Accelerated high dose radiation before surgery created a 65.9 month survival for mesothelioma patients. They were part of a clinical trial in Toronto at the Princess Margaret Cancer Center. The study is named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. There were 96 patients who were treated[…]
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.
Thoracic Chemotherapy After Surgery Could Help Pleural Mesothelioma Patients Survive Longer
Hyperthermic intrathoracic chemotherapy alongside aggressive therapy (HITHOC) could help extend pleural mesothelioma patient survival. Doctors perform this by circulating a heated high concentration chemotherapy solution in the chest cavity for one hour right after aggressive surgery is performed on a patient. They do this to kill microscopic tumor cells that[…]
Mesothelioma Chemotherapy Resistance Could be Due to Cell Hibernation
Canadian researchers have discovered a cause of chemotherapy resistance in mesothelioma and other cancers. This is great news because this can lead to new treatments being created to combat the incurable cancer. There are other types of treatments approved for mesothelioma, but they might not work and chemotherapy could be[…]
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Primary Outcome Measures Occurrence of Dose Limiting Toxicity [ Time Frame: over the first 21 days of dosing ] Incidence of Adverse and Serious Adverse Events Occurrence of General Toxicity [ Time Frame: through study completion, an average of 30 months ] Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations[…]
Skip to content